These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35171984)

  • 21. ABO and platelet transfusion revisited.
    Heal JM; Rowe JM; Blumberg N
    Ann Hematol; 1993 Jun; 66(6):309-14. PubMed ID: 8318561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion.
    Chavan A; Sharma RR; Saikia B; Malhotra P; Prakash S; Hans R; Marwaha N
    Transfus Apher Sci; 2019 Dec; 58(6):102657. PubMed ID: 31706911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.
    Fontaine MJ; Kuo J; Chen G; Galel SA; Miller E; Sequeira F; Viele M; Goodnough LT; Tyan DB
    Transfusion; 2011 Dec; 51(12):2611-8. PubMed ID: 21615749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABO-incompatible platelets are associated with increased transfusion reaction rates.
    Malvik N; Leon J; Schlueter AJ; Wu C; Knudson CM
    Transfusion; 2020 Feb; 60(2):285-293. PubMed ID: 31912889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC; Donnelly SF; Mintz PD
    Transfusion; 1994 Mar; 34(3):215-20. PubMed ID: 8146893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: A pilot study.
    Inoue H; Sakamoto R; Nishimiya H; Sakamoto H; Terasu S; Aminaka R; Koh Y; Takihara Y; Hirayama F; Kuroishi A
    Transfusion; 2021 Mar; 61(3):738-743. PubMed ID: 33166416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
    Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-Mediated Platelet Refractoriness.
    Schmidt AE; Refaai MA; Coppage M
    Am J Clin Pathol; 2019 Mar; 151(4):353-363. PubMed ID: 30285067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.
    Schiffer CA; O'Connell B; Lee EJ
    Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation.
    Jo T; Arai Y; Hatanaka K; Ishii H; Ono A; Matsuyama N; Mori J; Koh Y; Azuma F; Kimura T
    Cytotherapy; 2023 Apr; 25(4):407-414. PubMed ID: 36335019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
    Lee EJ; Schiffer CA
    Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study.
    Pavenski K; Warkentin TE; Shen H; Liu Y; Heddle NM
    Transfusion; 2010 Jul; 50(7):1552-60. PubMed ID: 20210928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation.
    Marktel S; Napolitano S; Zino E; Cappelli B; Chiesa R; Poli F; Crocchiolo R; Ronchi P; Rossini S; Ciceri F; Roncarolo MG; Fleischhauer K
    Pediatr Transplant; 2010 May; 14(3):393-401. PubMed ID: 20070557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of platelet crossmatch results by Solid Phase Red Cell Adherence Assay (SPRCA) with post-transfusion platelet count increment in adult hemato-oncology patients of a tertiary care oncology centre in India.
    Desai P; Sontakke P; Rajadhyaksha S; Navkudkar A
    Transfus Apher Sci; 2020 Oct; 59(5):102842. PubMed ID: 32586771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P; Purev E; West KA; McDuffee E; Worthy T; Cook L; Hawks G; Wells B; Shalabi R; Flegel WA; Adams SD; Reger R; Aue G; Tian X; Childs R
    Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.
    Musat AI; Pigott CM; Ellis TM; Agni RM; Leverson GE; Powell AJ; Richards KR; D'Alessandro AM; Lucey MR
    Liver Transpl; 2013 Oct; 19(10):1132-41. PubMed ID: 23873778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
    McVey M; Cserti-Gazdewich CM
    Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dilution is not the solution: acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion.
    Guarente J; Harach M; Gould J; Karp JK; Peedin AR
    Immunohematology; 2019 Sep; 35(3):91-94. PubMed ID: 31621366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.